CPHRF (Cipher Pharmaceuticals) Cyclically Adjusted FCF per Share: $0.63 (As of Mar. 2026)


CPHRF Cipher Pharmaceuticals Inc CPHRF
96 GF Score
Price $12.06
GF Value $12.20
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Cipher Pharmaceuticals Cyclically Adjusted FCF per Share?

Cipher Pharmaceuticals CPHRF +1.94% 96 Cyclically Adjusted FCF per Share is $0.63 as of Mar. 2026. GuruFocus rates CPHRF with a GF Score™ of 96/100 and a GF Value™ of $12.20 (Fairly Valued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Cipher Pharmaceuticals's adjusted free cash flow per share for the three months ended in Mar. 2026 was $0.154. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $0.63 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Cipher Pharmaceuticals's average Cyclically Adjusted FCF Growth Rate was 17.30% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 11.50% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 11.30% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 21.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Cipher Pharmaceuticals was 81.70% per year. The lowest was 7.20% per year. And the median was 13.80% per year.

As of today (2026-07-11), Cipher Pharmaceuticals's current stock price is $12.06. Cipher Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was $0.63. Cipher Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is 19.14.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Cipher Pharmaceuticals was 49.64. The lowest was 1.00. And the median was 7.00.


Cipher Pharmaceuticals  (OTCPK:CPHRF) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Cipher Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=12.06/0.63
=19.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Cipher Pharmaceuticals was 49.64. The lowest was 1.00. And the median was 7.00.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Cipher Pharmaceuticals Cyclically Adjusted FCF per Share Related Terms


Cipher Pharmaceuticals Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Cipher Pharmaceuticals's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cipher Pharmaceuticals Cyclically Adjusted FCF per Share Chart

Cipher Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.45 0.45 0.52 0.48 0.63

Cipher Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.52 0.56 0.59 0.63 0.63

CPHRF vs ZTS, UTHR: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Cipher Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cipher Pharmaceuticals Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cipher Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Cipher Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.


CPHRF
96GF Score
Cipher Pharmaceuticals Inc CPHRF
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cipher Pharmaceuticals Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Cipher Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.154/132.2623*132.2623
=0.154

Current CPI (Mar. 2026) = 132.2623.

Cipher Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 0.205 102.002 0.266
201609 0.187 101.765 0.243
201612 0.194 101.449 0.253
201703 0.042 102.634 0.054
201706 0.166 103.029 0.213
201709 0.269 103.345 0.344
201712 0.267 103.345 0.342
201803 0.113 105.004 0.142
201806 0.002 105.557 0.003
201809 0.011 105.636 0.014
201812 0.046 105.399 0.058
201903 0.013 106.979 0.016
201906 0.120 107.690 0.147
201909 0.071 107.611 0.087
201912 0.075 107.769 0.092
202003 0.172 107.927 0.211
202006 0.071 108.401 0.087
202009 -0.067 108.164 -0.082
202012 0.226 108.559 0.275
202103 0.159 110.298 0.191
202106 0.120 111.720 0.142
202109 0.019 112.905 0.022
202112 0.218 113.774 0.253
202203 0.074 117.646 0.083
202206 0.123 120.806 0.135
202209 0.165 120.648 0.181
202212 0.053 120.964 0.058
202303 0.183 122.702 0.197
202306 0.115 124.203 0.122
202309 0.232 125.230 0.245
202312 0.098 125.072 0.104
202403 0.100 126.258 0.105
202406 0.253 127.522 0.262
202409 0.077 127.285 0.080
202412 0.340 127.364 0.353
202503 0.161 129.181 0.165
202506 0.227 129.892 0.231
202509 0.411 130.287 0.417
202512 0.335 130.366 0.340
202603 0.154 132.262 0.154

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $0.63 mean?
Cipher Pharmaceuticals (CPHRF) has a Cyclically Adjusted FCF per Share of $0.63 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Cipher Pharmaceuticals and its competitors.
Is Cipher Pharmaceuticals' Cyclically Adjusted FCF per Share too high?
Cipher Pharmaceuticals' current Cyclically Adjusted FCF per Share is $0.63. Overall, Cipher Pharmaceuticals has a GF Score™ of 96/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cipher Pharmaceuticals' Cyclically Adjusted FCF per Share compare to ZTS and UTHR?
Cipher Pharmaceuticals' Cyclically Adjusted FCF per Share of $0.63 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Cipher Pharmaceuticals and its competitors. Cipher Pharmaceuticals's current Cyclically Adjusted FCF per Share is $0.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cipher Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Cipher Pharmaceuticals (CPHRF) is currently considered Fairly Valued. The stock's GF Value™ is $12.20, compared to a current price of $12.06 — trading 1.1% below its estimated fair value. The current Cyclically Adjusted FCF per Share is $0.63. Cipher Pharmaceuticals' overall GF Score™ is 96/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Cipher Pharmaceuticals (CPHRF), the current Cyclically Adjusted FCF per Share is $0.63 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cipher Pharmaceuticals (CPHRF) Overvalued in 2026?

Based on GuruFocus' analysis, Cipher Pharmaceuticals stock appears to be undervalued. The current stock price of $12.06 is trading 1.1% below its estimated GF Value™ of $12.20. GuruFocus considers Cipher Pharmaceuticals to be Fairly Valued.

Key valuation signals for CPHRF:

  • Cyclically Adjusted FCF per Share: $0.63
  • GF Value™: $12.20 vs. price of $12.06 (1.1% below fair value)
  • GF Score™: 96/100 with 5 warning signs

No single metric tells the full story. See the CPHRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cipher Pharmaceuticals Business Description

Other Exchanges PHE:GermanyCPH:Canada
Address 5750 Explorer Drive, Suite 404, Mississauga, ON, CAN, L4W 0A9
Cipher Pharmaceuticals Inc is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company is building its business through product acquisitions, out-licensing, and in-licensing arrangements. Its products include Dermatology Products, Hospital Acute Care Products, specialty medicines, and Out-Licensed Products, among others. The company's geographical operational areas include Canada and the United States.
96GF Score

Get the complete analysis for CPHRF

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.06
Price
$12.20
GF Value